Lise Gehrt

Lise Gehrt

Auto-generated profile, based on publicly available information

Lise Gehrt

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5230, Odense M, Denmark; Hans Christian Andersen Children's Hospital, Odense University Hospital, 5000, Odense C, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2022 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
NSNils Skajaa
Nils Skajaa
LGLise Gehrt
Lise Gehrt
HNHeta Nieminen
Heta Nieminen
ILIda Laake
Ida Laake
HEHélène Englund
Hélène Englund
SSSigne Sørup
Signe Sørup
Objective: To compare the use of antibiotics in children in four Northern European countries. Methods: We conducted a register-based study based on individual-level prescription data from national prescription registers. We identified all redeemed outpatient prescriptions for systemic antibiotics in children aged 0– 14 years from July 2006 to June 2017 in Denmark, Finland, Norway, and Sweden. We computed incidence rates and incidence rate ratios of treatment episodes with any antibiotic and different antibiotic classes. Results: In 2016/2017, the rates of antibiotic treatment episodes per 1000 person-years in children aged 0– 14 years were 429, 284, 219, and 184 in Finland, Denmark, Sweden, and Norway, respectively, and the rate ratios (95% confidence intervals) compared with Norway were 2.33 (2.33– 2.34), 1.54 (1.54– 1.55), and 1.19 (1.19– 1.20) in Finland, Denmark, and Sweden, respectively. The rate of antibiotic treatment episodes declined over time in all countries. The relative reductions in 2016/2017 compared with 2006/2007 were 36% in Finland, 40% in Denmark, 49% in Sweden, and 29% in Norway. Treatment episodes peaked between age 12 and 18 months. The most used antibiotic class was beta-lactamase sensitive penicillins among all children in Norway and Sweden and among children above two years in Denmark, while penicillins with extended spectrum were most used in Finland and among the youngest children in Denmark. Conclusion: In all countries, the use of antibiotics in children declined between 2006 and 2017. However, there were still considerable differences in antibiotic use between otherwise quite similar Nordic countries, with a more than 2-fold difference between the countries with the lowest and highest rates. Interventions to reduce the number of antibiotic treatment episodes in the countries with higher rates could reduce the total antibiotic use.

1 April 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
LGLise Gehrt
Lise Gehrt
ARAndreas Rieckmann
Andreas Rieckmann
NKNicholas Kiraly
Nicholas Kiraly
AJAksel Karl Georg Jensen
Aksel Karl Georg Jensen
PAPeter Aaby
Peter Aaby
SSSigne Sørup
Signe Sørup

1 April 2022 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
LGLise Gehrt
Lise Gehrt
ILIda Laake
Ida Laake
HEHélène Englund
Hélène Englund
HNHeta Nieminen
Heta Nieminen
CBChristine Stabell Benn
Christine Stabell Benn
SSSigne Sørup
Signe Sørup
Purpose: Comparing rates of childhood infectious disease hospitalisations across countries may uncover areas for improvement in the prevention of severe childhood infections. We compared rates of childhood infectious disease hospital contacts across Denmark, Finland, Norway, and Sweden with the overall objective to elucidate potential differences in burden of disease and in organisational and registration practices. Methods: Using national registries, we estimated incidence rates for infectious disease hospital contacts between 2008 and 2017 among children aged 0– 14 years. We investigated the rates for different types of contacts (inpatient or outpatient including emergency room), duration of admission, and by sex. Results: During the study period, the rate of all hospital contacts per 1000 person-years was highest in Sweden (125.2) followed by Finland (87.1), Denmark (79.0), and Norway (62.1). The rates aligned for inpatient contacts with overnight stays; 19.3 (Denmark), 16.6 (Finland), 16.3 (Norway), and 13.0 (Sweden); these were highest in early infancy in all countries. A peak around 1 year of age was seen in all countries except in Sweden. The rates were higher among boys compared with girls in early childhood, after 13 years of age the rates among girls surpassed the boys. Conclusion: Large cross-country differences were observed for outpatient and short-term hospital contacts for infectious diseases, affected by differences in organisational structures and coding practices across and within countries over time. Inpatient contacts requiring overnight stays reflected more comparable levels of severe infections across countries. Childhood infectious disease morbidity was greatest among boys and before 2 years of age.

30 October 2019 in Infectious Diseases
Verified
Journal Article
Closed access
JLJacob W. W. Larsen
Jacob W. W. Larsen
ASAnders F. Sørensen
Anders F. Sørensen
AJAksel K. G. Jensen
Aksel K. G. Jensen
APAnja Poulsen
Anja Poulsen
LGLise Gehrt
Lise Gehrt
SSSigne Sørup
Signe Sørup
Background: Infectious diseases are a major cause of hospitalizations in children and there is increasing interest in sex differences in immunity during childhood. Therefore, we examined hospital admission rates for infectious diseases in Danish children by age and sex. Methods: Register-based cohort study of all Danish residents aged 0–14 years from 1977 to 2014. We examined total admission rate for infections and rates of admission by types of infection. Results: This study included 3,689,999 children and 1,080,750 admissions for infections. The admission rates peaked at age 0 months (boys, 197.9 admissions per 1000 person-years; girls, 160.9) and age 11 months (boys, 155.5; girls, 113.9). The male–female ratio of admissions was 1.25 for children aged 0–14 years, but varied by age and type of infection. Boys had the highest admission rate for any infection until 9 years of age after which girls had a higher rate. Boys had higher admission rates for gastrointestinal infections and lower respiratory tract infections than girls at all ages. The admission rates for upper respiratory tract infections and ‘Other infections’ for girls were higher than the rates for boys at age 10 and 4 years, respectively. Conclusions: Overall, boys had around 25% higher admission rates for infections than girls, with some variation according to age and type of infection.

17 October 2024 in Journal of Infection
Verified
Journal Article
Open access
AMAnne Marie Rosendahl Madsen
Anne Marie Rosendahl Madsen
LGLise Gehrt
Lise Gehrt
FSFrederik Schaltz-Buchholzer
Frederik Schaltz-Buchholzer
Sören MöllerSören Möller
Sören Möller
RCRikke Christiansen
Rikke Christiansen
CBChristine Stabell Benn
Christine Stabell Benn
The Bacillus Calmette-Guérin (BCG) vaccine may induce non-specific protection against unrelated infections. We tested the effect of BCG on the risk of infections among Danish senior citizens. Single-blinded randomised controlled trial including 1676 volunteers >65 years. Participants were randomised 1:1 to BCG or placebo and followed for 12 months. The primary outcome was acute infection leading to medical contact. Secondary outcomes were verified SARS-CoV-2 infection, self-reported respiratory symptoms, and all-cause hospitalisation. Data was analysed using Cox regression models, estimating hazard ratios (HR) with 95% confidence intervals (CI). The incidence of acute infection was 52.1 and 58.2 per 100 person-years for BCG and placebo, respectively (HR=0.89, 95% CI=0.78-1.02). There was no effect of BCG on SARS-CoV-2 infections (0.97, 0.75-1.26) or all-cause hospitalisations (1.10, 0.80-1.50), but BCG was associated with more respiratory symptoms (1.21, 1.10-1.33). BCG reduced the incidence of acute infections among participants 75 years (1.14, 0.88-1.47). In participants, who were COVID-19 vaccinated before enrolment, BCG was associated with lower incidence of acute infections (0.65, 0.50-0.85). BCG did not reduce risk of acute infections among Danish seniors overall, but the effect was modified by age group and COVID-19 vaccination. ClinicalTrials.gov (NCT04542330) and EU Clinical Trials Register (EudraCT number 2020-003904-15). Full trial protocol is available at ClinicalTrials.gov. In a randomised clinical trial among Danish senior citizens, BCG vaccination did not reduce the overall risk of acute infection, but BCG was associated with reduced risk in participants <75 years and participants who received COVID-19 vaccines prior to enrolment.

10 February 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
LGLise Gehrt
Lise Gehrt
ILIda Laake
Ida Laake
HEHélène Englund
Hélène Englund
HNHeta Nieminen
Heta Nieminen
BFBerit Feiring
Berit Feiring
SSSigne Sørup
Signe Sørup
Purpose The aim of the NONSEnse project is to investigate the non-specific effects of vaccines and immunisation programmes on the overall health of children by using information from the extensive nationwide registers on health and sociodemographic factors in Denmark, Finland, Norway and Sweden. Participants The cohort covers 9 072 420 children aged 0–17 years, born 1990–2017/2018 and living in Denmark, Finland, Norway or Sweden. All countries use a unique identification number for its permanent residents, which makes it possible to link individual-level information from different registers. Findings to date Data collection and harmonisation according to a common data model was completed in March 2022. As a prerequisite for comparing the effects of childhood vaccinations on the overall health of children across the Nordic countries, we have identified indicators measuring similar levels of infectious disease morbidity across these settings. So far, studies pertaining to non-specific effects of vaccines are limited to investigations that could be undertaken using aggregated data sets that were available before the NONSEnse cohort with individual-level information was completely set up. Future plans We are currently performing several studies of the effects on non-targeted infectious disease morbidity across the countries following vaccination against measles, mumps, rubella, diphtheria, tetanus, pertussis, human papillomavirus, rotavirus and influenza. Multiple studies are planned within the next years using different study designs to facilitate triangulation of results and enhance causal inference. Registration No clinical trials will be conducted within the NONSEnse project.